|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 January 2002, Vol. 99, No. 1, pp. 381-383
BRIEF REPORT
Treatment of chronic myelogenous leukemia with the tyrosine
kinase inhibitor STI571 results in marked regression of bone
marrow fibrosis
Christine Beham-Schmid,
Ute Apfelbeck,
Heinz Sill,
Oleksiy Tsybrovsky,
Gerald Höfler,
Oskar A. Haas, and
Werner Linkesch
From the Institute of Pathology and the Division of
Hematology, Department of Medicine, Karl-Franzens University, Graz,
Austria; and the Children's Cancer Research Institute, St Anna
Children's Hospital, Vienna, Austria.
Morphologic bone marrow changes in patients with BCR-ABL-positive
chronic myelogenous leukemia (CML) were investigated during treatment
with the tyrosine kinase inhibitor STI571. Bone marrow trephine biopsy
specimens from 23 pretreated patients with CML were examined
morphologically and by morphometry before and 6 weeks and 3 months
after the initiation of STI571 therapy (Glivec, Novartis, Basel,
Switzerland). Bone marrow changes during treatment showed a
quantitative normalization of erythropoiesis, a marked reduction of
granulopoiesis, and a significant decrease in megakaryocytes with the
reappearance of normal-sized forms. Furthermore, a significant regression of bone marrow fibrosis was observed in patients with initial fibrosis (P < .000 000 001). These results may
expand the profile of STI571 and may offer novel therapeutic
possibilities in diseases with bone marrow fibrosis.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Akhmetshina, C. Dees, M. Pileckyte, B. Maurer, R. Axmann, A. Jungel, J. Zwerina, S. Gay, G. Schett, O. Distler, et al.
Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis
FASEB J,
July 1, 2008;
22(7):
2214 - 2222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
Primary myelofibrosis and its paraneoplastic stromal effects
Haematologica,
May 1, 2007;
92(5):
577 - 579.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Arana-Yi, A. Quintas-Cardama, F. Giles, D. Thomas, A. Carrasco-Yalan, J. Cortes, H. Kantarjian, and S. Verstovsek
Advances in the Therapy of Chronic Idiopathic Myelofibrosis
Oncologist,
September 1, 2006;
11(8):
929 - 943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Martelli, B. Ghinassi, B. Panetta, E. Alfani, V. Gatta, A. Pancrazzi, C. Bogani, A. M. Vannucchi, F. Paoletti, G. Migliaccio, et al.
Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds
Blood,
December 15, 2005;
106(13):
4102 - 4113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Aono, Y. Nishioka, M. Inayama, M. Ugai, J. Kishi, H. Uehara, K. Izumi, and S. Sone
Imatinib as a Novel Antifibrotic Agent in Bleomycin-induced Pulmonary Fibrosis in Mice
Am. J. Respir. Crit. Care Med.,
June 1, 2005;
171(11):
1279 - 1285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Yoshiji, R. Noguchi, S. Kuriyama, Y. Ikenaka, J. Yoshii, K. Yanase, T. Namisaki, M. Kitade, T. Masaki, and H. Fukui
Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats
Am J Physiol Gastrointest Liver Physiol,
May 1, 2005;
288(5):
G907 - G913.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Vannucchi, L. Bianchi, F. Paoletti, A. Pancrazzi, E. Torre, M. Nishikawa, M. Zingariello, A. Di Baldassarre, R. A. Rana, R. Lorenzini, et al.
A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-{beta}1 in the development of myelofibrosis
Blood,
May 1, 2005;
105(9):
3493 - 3501.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Grun, B. Markova, F.-D. Bohmer, A. Berndt, H. Kosmehl, and C. Leipner
Elevated expression of PDGF-C in coxsackievirus B3-induced chronic myocarditis
Eur. Heart J.,
April 1, 2005;
26(7):
728 - 739.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pardanani and A. Tefferi
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders
Blood,
October 1, 2004;
104(7):
1931 - 1939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Kvasnicka, J. Thiele, P. Staib, A. Schmitt-Graeff, M. Griesshammer, J. Klose, K. Engels, and S. Kriener
Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy
Blood,
May 1, 2004;
103(9):
3549 - 3551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. K. Pryer, L. B. Lee, R. Zadovaskaya, X. Yu, J. Sukbuntherng, J. M. Cherrington, and C. A. London
Proof of Target for SU11654: Inhibition of KIT Phosphorylation in Canine Mast Cell Tumors
Clin. Cancer Res.,
November 15, 2003;
9(15):
5729 - 5734.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. O. Martinez, B. Agerholm-Larsen, N. Wang, W. Chen, and A. R. Tall
Phosphorylation of a Pest Sequence in ABCA1 Promotes Calpain Degradation and Is Reversed by ApoA-I
J. Biol. Chem.,
September 26, 2003;
278(39):
37368 - 37374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
